Cardiac arrhythmias after cisplatin infusion: Three case reports and a review of the literature

Annals of Oncology

Volumn 8, Issue 12, 1997, Pages 1263-1267

  Tassinari, D ^a,d   Sartori, S ^b   Drudi, G ^a   Panzini, I ^a   Gianni, L ^a   Pasquini, E ^a   Abbasciano, V ^c   Ravaioli, A ^a   Iorio, D ^a  

^a City Hospital   (Italy)

^b UNIVERSITY HOSPITAL OF FERRARA   (Italy)

^c UNIVERSITY OF FERRARA   (Italy)

^d NONE   (Italy)

Author keywords

Cardiac arrhythmias; Chemotherapy; Cisplatin; Magnesium depletion; Side effects

Indexed keywords

ALPHA INTERFERON; AMSACRINE; BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; INTERLEUKIN 1; INTERLEUKIN 11; INTERLEUKIN 2; IRINOTECAN; PACLITAXEL; VINCRISTINE;

AGED; ARTICLE; CARDIOTOXICITY; CASE REPORT; DRUG MECHANISM; DYSPNEA; HEART ATRIUM FIBRILLATION; HEART PALPITATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; MALE; PRIORITY JOURNAL; SUPRAVENTRICULAR TACHYCARDIA;

AGED; ANTINEOPLASTIC AGENTS; CISPLATIN; HUMANS; MAGNESIUM; MALE; TACHYCARDIA, SUPRAVENTRICULAR;

EID: 0031462142     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008231521553     Document Type: Article

References (54)

1. Hochster H, Wasserheit C, Speyer J. Cardiotoxicity and cardio-protection during chemotherapy. Curr Opin Oncol 1995; 7: 304-9.
2. Allen A. The cardiotoxicity of chemotherapeutic drugs. Semin Oncol 1992; 18 (5): 529-42.
3. Steinherz L, Yahalom J. Cardiac toxicity. In De Vita VT Jr, Hellman S, Rosemberg SA (eds): Cancer. Principles and Practice of Oncology 5th ed. Philadelphia: Lippincot Raven 1997; 2739-56.
4. Brestescher C, Pautier P, Farge D. Chemotherapy and cardiotoxicity. Ann Cardiol Angiol 1995; 44 (8): 443-8.
5. Loehrer PJ, Einhorn LH. Cisplatin. Ann Intern Med 1984; 100: 704-13.
6. Zumkley H, Bertram HP, Preusser P et al. Renal excretion of magnesium and trace elements during cisplatin treatment. Clin Nephrol 1982; 17: 254-7.
7. Shilsky RL, Anderson T. Hypomagnesemia and renal magnesium wasting in patients receiving cisplatin. Ann Intern Med 1979; 90: 929-31.
8. Bell DR, Woods RL, Levi JA. Cis-diammine-dichloreplatinum-induced hypomagnesemia and renal magnesium wasting. Eur J Cancer Clin Oncol 1985; 21: 287-90.
9. Buckley JE, Clark VL, Meyer TJ et al. Hypomagnesemia after cisplatin combination chemotherapy. Arch Intern Med 1984; 144: 2347-8.
10. Blackley JO, Hill JB. Renal and electrolyte disturbances associated with cisplatin. Ann Intern Med 1981; 95: 628-32.
11. Menard O, Martinet Y, Lamy P. Cisplatin-induced atrial fibrillation. J Clin Oncol 1991; 9: 192-3 (Letter).
12. Petrella V, Alciato P, Cantone PA et al. High-frequency atrial arrhythmia induced by a cisplatin-etoposide combination. Min Med 1989; 80: 305-7.
13. Cannobbio L, Fassio T, Gasparini G et al. Cardiac arrhythmia: Possible complication from treatment with cisplatin. Tumori 1986; 72: 201-4.
14. Locatelli C, Fagioli F, Mazzotta D et al. Determination of magnesium in erythrocytes by atomic absorption spectrophotometry. Annali di Chimica 1987; 78: 163-8.
15. Bristow MR,Thompson PD, Martin RP et al. Early anthracycline cardiotoxicity. Am J Med 1978; 65: 823-32.
16. Praga C, Beretta G, Vigo PL et al. Adriamycin cardiotoxicity: A survey of 1273 patients. Cancer Treat Rep 1979; 827-34.
17. Sartori S, Nielsen I, Tassinari D et al. Intracellular magnesium concentrations and acute anthracycline-induced cardiotoxicity. Br J Cancer 1991; 64: 785-7.
18. Wortman JE, Lucas VS, Schuster E et al. Sudden death during doxorubicin administration. Cancer 1979; 44: 1588-91.
19. Bristow MR, Billingham ME, Mason JW et al. Clinical spectrum of anthracycline antibiotic cardiotoxicity. Cancer Treat Rep 1978; 6: 873-9.
20. Steinherz L, Steinherz P. Delayed cardiac toxicity from anthracycline therapy. Pediatrician 1991; 18: 49-52.
21. Mladosievicova B, Hulin I, Krcmery V Jr et al. Pathogenesis, prevention and detection of cardiotoxicity of anthracycline cytostatic agents. Bratisl Lek Listy 1994; 95 (7): 304-22.
22. Burtness B, Harrold L, Beaulieu N et al. Use of paclitaxel in patients with cardiomyopathy is safe (meeting abstract). Proc Annu Meet Am Soc Clin Oncol 1996; 15: 252.
23. Seidman AD,Tiersten A, Hudis C et al. Phase II trial of paclitaxel by 3-hour infusion as initial and salvatage chemotherapy for metastatic breast cancer. J Clin Oncol 1995; 13 (10): 2575-81.
24. Zaheer W, Lichtman SM, De Marco L et al. The use of taxol in elderly patients (meeting abstract). Proc Annu Meet Am Soc Clin Oncol 1994; 13: 1518.
25. Schiller JH, Storer B, Tutsch K et al. A phase I trial of 3-hour infusion of paclitaxel (Taxol) with or without granulocyte colony-stimulating factor. Semin Oncol 1994; 21 (5): 9-14 (Suppl 8).
26. Rowinsky EK, Mc Guire WP, Donehower RC. The current status of taxol. Prin Pract Gynecol Oncol Updates 1993; 1 (1): 1-16.
27. Rowinsky EK, Mc Guire WP, Guarnieri T et al. Cardiac disturbances during the administration of taxol. J Clin Oncol 1991; 9: 1704-21.
28. Arbuck S, Strauss H, Rowinsky E et al. A reassessment of cardiac toxicity associated with taxol. Monogr Natl Cancer Inst 1993; 15: 117-30.
29. Gottdeiner J, Appelbaum F, Ferrans V et al. Cardiotoxicity associated with high-dose cyclophosphamide therapy. Arch Intern Med 1981; 141: 758-63.
30. Cazin B, Gorin N, Laporte J et al. Cardiac complications after bone marrow transplantation: A report on a series of 63 consecutive transplantations. Cancer 1986; 57: 2061-9.
31. Pottage A, Holt S, Ludgate S et al. Fluorouracil cardiotoxicity. BMJ 1978; 6112: 547.
32. Labianca R, Beretta G, Clerici M et al. Cardiac toxicity of 5-fluorouracil: A study on 1083 patients. Tumori 1982; 68: 505-10.
33. Mancuso L, Bondi F, Marchi S et al. Cardiac toxicity of 5-fluorouracil. Report of a case of spontaneous angina. Tumori 1986; 72: 121-4.
34. Escudier B, Conscience G, Nkam M et al. Cardiotoxicity du 5 fluorouracile. A propos d'un noveau cas Arch Mal Coeur 1985; 10: 1579-81.
35. Raina A, Ferrante F, Bisol A et al. Cardiotoxicity during chemotherapy for advanced gastroenteric tumors. Tumori 1987; 73: 359-61.
36. Esklisson J, Albertsson M, Mercke C. Adverse cardiac effects during induction chemotherapy tretatment with cisplatin and 5-fluorouracil. Radiother Oncol 1988; 13: 41-6.
37. Seymour JF. Induction of hypomagnesemia during amsacrine treatment. Am J Hematol 1993; 42 (3): 262-7.
38. Weiss RB, Grillo Lopez AJ, Marsoni S et al. Amsacrine-associated cardiotoxicity: An analysis of 82 cases. J Clin Oncol 1986; 4: 918-28.
39. Steinherz LJ, Steinherz PG, Mangiacasale D et al. Cardiac abnormalities after AMSA administration. Cancer Treat Rep 1982; 66: 483-8.
40. Marincola FM. Interleukin-2. Biol Ther Cancer Updates 1994; 4 (3): 1-16.
41. Nora R, Abrams JS, Tait NS et al. Myocardial toxicity effects during IL-2 therapy. J Natl Cancer Inst 1989; 81: 59-63.
42. Kruit WH, Punt KJ, Goey SH et al. Cardiotoxicity as a dose limiting factor in a schedule of high dose bolus therapy with interleukin-2 and alpha interferon: An unexpectedly frequent complication. Cancer 1994; 74: 2850-6.
43. Threhu EG, Isner JM, Mier JW et al. Possible myocardial toxicity associated with interleukin-4 therapy. J Immunother 1993; 14: 348-51.
44. Tepler I, Elias L, Smith JW et al. A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Blood 1996; 87 (9): 3607-14.
45. Keung YK, Lau S, Elkayam U et al. Cardiac arrhythmia after infusion of cryopreserved stem cells. Bone Marrow Transplant 1994; 14: 363-7.
46. Lopez-Jemenez J, Cervero C, Munoz A et al. Cardiovascular toxicities related to the infusion of cryopreserved grafts: Results of a controlled study. Bone Marrow Transplant 1994; 13: 789-93.
47. Talley RS, O'Bryan RM, Gutterman JA et al. Clinical evaluation of toxic effects of cis-diamminedichloro-platinum (NSC-119875). Phase I clinical study. Cancer Chemother Rep 1973; 57: 465-71.
48. Hashimi LA, Khalyl MF, Salem PA. Supraventricular tachycardia. A probable complication of platinum treatment. Oncology 1984; 41: 174-5.
49. Abbasciano V, Mazzotta D, Vecchiatti G et al. Changes in serum, erythrocyte and urinary magnesium after a single dose of cisplatin combination chemotherapy. Magnesium Res 1991; 4:123-5.
50. Sartori S, Nielsen I, Tassinari D et al. Changes in intracellular magnesium concentrations during cisplatin chemotherapy. Oncology 1993; 50: 230-4.
51. Iseri LT. Magnesium in coronary artery disease. Drugs 1984; 28 (Suppl 1): 151-60.
52. Durlach J. Methods of evaluating magnesium status. In Durlach J (ed): Magnesium in Clinical Practice, 1st edition. London: John Libbey & Co. 1988; 40-60.
53. Altura BM, Altura BT. New perspective on the role of magnesium in the pathophysiology of cardiovascular system. Magnesium 1985; 4: 245-71.
54. Dyckner T, Wester PO. Magnesium in cardiology. Acta Med Scand 1982; 661 (Suppl): 27-31.